We used CD39 as a marker of putative tumor-reactive CD8+ T cells, as recently proposed in different types of cancer including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, colorectal cancer and melanoma31,33,35,36 (Fig. 3a). Here, ENTPD1 is linked to non-small cell lung carcinoma.